Potassium Chloride Sustained Release Tablets

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L; while the main cation outside cells is sodium ion, with a potassium concentration of only 3.5-5 mmol/L. The body mainly relies on Na+-K±ATPase on the cell membrane to maintain the concentration difference between K+ and Na+ in cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference of the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal intracellular and extracellular potassium ion concentration and concentration difference are closely related to some important functions of cells, including maintaining carbohydrate metabolism, glycogen storage, protein metabolism, intracellular osmotic pressure and acid-base balance, myocardial excitability and conductivity; maintaining normal skeletal muscle tension and nerve impulse conduction, and increasing the tension of intestinal, uterine and bronchial smooth muscles.

The main ingredient of this product and its chemical name is potassium chloride.

This product is a sugar-coated tablet, which appears white after removing the coating.

1. Treatment of hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, use of potassium-excreting diuretics, hypokalemic familial periodic paralysis, long-term use of glucocorticoids and supplementation of hypertonic glucose, etc. 2. Prevention of hypokalemia When patients have potassium loss, especially if hypokalemia is harmful to patients (such as patients with digitalis), preventive potassium salt supplementation is required, such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, and Bartter’s syndrome, etc. 3. Digitalis poisoning causes frequent, multifocal premature beats or rapid arrhythmias.

Adults take 0.5g to 1g each time, 2 to 4 times a day, after meals, and adjust the dose according to the condition. The maximum daily dose for adults is 6g. For those who have gastrointestinal reactions to oral tablets, oral solution can be used instead, diluted in cold boiled water or beverages for oral administration.

1 Oral administration may occasionally cause gastrointestinal irritation symptoms, such as nausea, vomiting, throat discomfort, chest pain (esophageal irritation), abdominal pain, diarrhea, and even peptic ulcer and bleeding. It is more likely to occur when the patient is fasting, takes a large dose, or has existing gastrointestinal diseases. 2 Hyperkalemia. It is more likely to occur when the patient is overdosed or has existing renal impairment. It manifests as weakness, fatigue, numbness of the hands, feet, lips, and mouth, unexplained anxiety, confusion, dyspnea, slow heart rate, arrhythmia, conduction block, and even cardiac arrest. The electrocardiogram shows a high and sharp T wave, and the P-R interval gradually becomes prolonged. The P wave disappears, the QRS wave becomes wider, and a sine wave appears. Once hyperkalemia occurs, it should be treated immediately. (1) Immediately stop potassium supplementation, avoid potassium-containing diets, drugs, and potassium-sparing diuretics. (2) Intravenous infusion of high-concentration glucose injection and insulin to promote the entry of K into cells, 10% to 25% glucose injection 300 to 500 ml per hour. Add 10 units of regular insulin to every 20g of glucose. (3) If metabolic acidosis is present, 5% sodium bicarbonate injection should be used immediately. For those without acidosis, 11.2% sodium lactate injection can be used, especially for those with widened QRS waves. (4) Use calcium to counteract the cardiac toxicity of K. When the electrocardiogram shows a lack of P waves, widened QRS waves, and arrhythmias, and digitalis drugs are not used, 10% calcium gluconate injection 10ml can be given, intravenously for 2 minutes, and repeated at intervals of 2 minutes if necessary. (5) Oral potassium-lowering resins are used to block intestinal K absorption and promote intestinal K excretion. (6) Severe hyperkalemia accompanied by renal failure. Hemodialysis or peritoneal dialysis can be performed, and hemodialysis has a better effect and faster rate of removing K. (7) Use loop diuretics and supplement with normal saline if necessary.

Hyperkalemia; patients with scanty urine output and urinary retention.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Not clear yet. Precautions for the elderly: The kidneys of the elderly have a reduced ability to clear potassium, and hyperkalemia is more likely to occur when potassium salts are used. Follow-up checks of blood potassium should be performed during medication.

1. Adrenal glucocorticoids, especially those with more obvious mineralocorticoid effects, adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used together, they reduce the efficacy of potassium salts. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Nonsteroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When using stored blood (30mmol/L of potassium for less than 10 days of storage, 65mmol/L of potassium for more than 10 days of storage), taking potassium-containing drugs and potassium-sparing diuretics, the chance of hyperkalemia increases, especially in patients with renal impairment. 5. Angiotensin-converting enzyme inhibitors and cyclosporine can inhibit aldosterone secretion, reduce urinary potassium excretion, and are prone to hyperkalemia when used together. 6. Heparin can inhibit the synthesis of aldosterone, reduce urinary potassium excretion, and are prone to hyperkalemia when used together; in addition, heparin can increase the chance of gastrointestinal bleeding. 7. Sustained-release potassium salt can inhibit the intestinal absorption of vitamin B12.

Seal and store in a dry place (10-30℃).

0.5 g

24 months.

Shanghai Haihong Industry (Group) Chaohu Jinchen Pharmaceutical Co., Ltd.

• Founded in:

  2002-11-26

• Address:

  No. 18, Yicheng Road, Chaohu City, Anhui Province

• Tax NO.:

  91340181744869155N

• Registered Funds:

  31 million yuan

• Website:

  Log in to view

• Email:

  Log in to view